Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29262767 | 0.80 | KCNN4 (0.61) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL2273209 | 0.80 | KCNN4 (0.57) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL12264150 | 0.78 | KCNN4 (0.50) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| Water SCHEMBL28025033 | 0.78 | KCNN4 (0.55) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL316124 | 0.78 | KCNN4 (0.55) | KCNN4TSHRCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL2392958 | 0.77 | KCNN4 (0.49) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL2223266 | 0.77 | KCNN4 (0.44) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL11718872 | 0.77 | KCNN4 (0.44) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL2390487 | 0.77 | KCNN4 (0.44) | KCNN4HTR2AHTR2COPRK1KCNH2 | |
| SCHEMBL12264151 | 0.76 | KCNN4 (0.47) | KCNN4HTR2AHTR2COPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068488-A1 | METHOD FOR SYNTHESISING PEPTIDIC COMPOUNDS, IN PARTICULAR ARGININE RESIDUES-CONTAINING PEPTIDIC COMPOUNDS ON A SOLID SUPPORT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-07-28 | — | — | WO | claimed |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3215116-B1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIV OF THE SCIENCES IN PHILADELPHIA (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2019-04-23 | — | — | US | disclosed |
| US-10005816-B2 | Peptides and their use in food and beverage | The Folger Coffee Company (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3215116-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | University of the Sciences in Philadelphia (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | SWK FUNDING LLC | 2004-04-22 | — | — | US | disclosed |
| EP-1328510-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LTD. (GB) | 2003-07-23 | — | — | EP | disclosed |
| US-6531499-B2 | Guanidine and acylurea derivatives as anticancer, antishock, and antiinflammatory agents | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| US-20020032347-A1 | Matrix metalloproteinase inhibitors and method of using same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-03-14 | — | — | US | disclosed |
| US-6294694-B1 | INHIBIT ENDOTOXIC SHOCK, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, PROLIFERATION OF CANCER CELLS, INVASION OF BASEMENT MEMBRANES BY CANCER CELLS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-09-25 | — | — | US | disclosed |
| WO-2000075106-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHOD OF USING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | KCNN4 4812/4885HTR2A 4644/4885HTR2C 4786/4885 |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | KCNN4 4483/4885HTR2A 1312/4885HTR2C 1820/4885 |
| US-20020032347-A1 | Matrix metalloproteinase inhibitors and method of using same | MMP25, MMP17, MMP2 | KCNN4 3465/4885HTR2A 3758/4885HTR2C 3935/4885 |
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | MMP2, DNASE1L3, DNASE1 | KCNN4 4626/4885HTR2A 2687/4885HTR2C 3666/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | KCNN4 4483/4885HTR2A 1312/4885HTR2C 1820/4885 |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | MMP2, DNASE1L3, DNASE1 | KCNN4 4626/4885HTR2A 2687/4885HTR2C 3666/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | KCNN4 4483/4885HTR2A 1312/4885HTR2C 1820/4885 |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC2 | KCNN4 3058/4885HTR2A 1487/4885HTR2C 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.